Generic Name and Formulations:
Cabergoline 0.5mg; scored tabs.
Various generic manufacturers
Indications for Cabergoline:
Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors.
Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly.
Uncontrolled hypertension. Sensitivity to ergot alkaloids.
Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives.
GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy.
Formerly known under the brand name Dostinex.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age